Autolus Therapeutics

AUTL

Biotechnology · Healthcare

Price

$1.44

-0.02 (-1.37%)

Market Cap

$383.2M

Exchange

NASDAQ

Winston Score

Winston is worried

Weak fundamentals across most pillars.

Share count rising — dilution

+269.2% over 4y

The company has issued more shares over this period, which dilutes each existing shareholder’s stake.

Diluted shares outstanding: 72.1M (2021) → 266.1M (2025)

Autolus Therapeutics is a British biotechnology company that develops cancer treatments using a technology called CAR-T cell therapy. This approach takes a patient's own immune cells, engineers them in a lab to recognize and attack cancer cells, and then puts them back into the patient's body. The company's lead product, Aucatzyl (obecabtagene autoleucel), was approved by the FDA in 2024 to treat a type of blood cancer called B-cell acute lymphoblastic leukemia in adults.

Autolus makes money by selling Aucatzyl to hospitals and cancer treatment centers in the United States, where it is currently launching the product commercially. The company is small, with a market cap around $500 million, and it is still spending far more than it earns, which is typical for early-stage biotech firms. The key growth driver is how quickly Aucatzyl gains adoption among oncologists, while the main risk is that the company may need to raise additional cash to fund operations before reaching profitability.

Winston Score History

Growth Profile

For growth stock investors

When traditional metrics don't capture the full picture, these are the signals growth stock investors use instead.

Revenue Growth

+191.9% YoY

YoY Growth Rate

Strong revenue growth

EPS Growth

-3.8% YoY

YoY Growth Rate

Earnings declining

R&D Spend

$129M/ year

↓ Declining (-19% vs prior year)

170.2% of revenue

9.5x the sector average (18%)

R&D spend declining — could signal cost-cutting or efficiency

Insider Activity

9.6%ownership

→ Flat

Insiders holding steady — not selling despite ability to

Cash Runway

~6 months

$131M cash & investments

Quarterly Free Cash Flow

↓ Burn rate worsening

Short runway — potential dilution ahead through share issuance

Strong grower

Autolus Therapeutics is growing revenue at 192% year-over-year. The Winston Score penalises unprofitable companies, but revenue at this pace tells a different story — this is a company still in "build mode."

The Winston Score above measures business quality today. Growth stocks often score lower because they invest in the future rather than maximising current profits. These metrics show what matters most for evaluating that future.

Score breakdown

Every number that matters to educated investors.

Each metric is explained in plain language so you know exactly what you're looking at. Start your free trial now.

Quality

Gross Margin

6.3%

Thin — 6.3% gross margin

Operating Margin

-227.0%

Losing money on operations — -227.0%

ROCE

-31.5%

Weak — -31.5% return on capital

Negative ROIC means the business is losing money on every dollar invested in it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Growth

Sales YoY

+927.5%

Fast-growing sales (927.5% YoY)

EPS YoY

N/A

—

Data not available

EPS Consistency

0/8 quarters

Earnings rarely grow — volatile business

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Cash Flow

Cash Conversion

N/A

—

Data not available

FCF Margin

-345.5%

Burning cash (-345.5%)

Free cash flow is negative. They are burning cash, not generating it.

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Stability

Debt / Equity

0.73

Moderate — manageable debt (0.73)

Interest Cover

N/A

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Valuation

P/E Ratio (TTM)

N/M

—

Negative earnings — P/E not meaningful

P/E vs Forward

N/A

not available

Data not available

Full breakdown available with your free trial

See every metric, trend, and what it means for this stock.

Try free

Dividends

Not applicable for this business.

🔒 See full fundamentals and if they are improving or declining — click here for your free trial now.

Start free trial